ArticleJBMR plus2026
Effects of hydroxybisphosphonates-conjugated sitafloxacin on fracture healing and skeletal growth in mice.
Article in JBMR plus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Implant-associated osteomyelitis is extremely difficult to treat due to bacterial colonization of the osteocyte-lacuno canalicular network, where bacteria are inaccessible from immune clearance and antibiotic treatment. The pharmacokinetic limitations of drug delivery to this compartment of bone render this infection resistant to standard-of-care antibiotics. Bone-targeted bisphosphonate-conjugated antibiotics have been developed to overcome this issue, and hydroxybisphosphonate-conjugated sitafloxacin (HBCS) has emerged as a leading therapeutic candidate based on safety and efficacy results in mice and sheep. However, potential concerns about its adverse effects on skeletal growth and bone healing remain. To address this, we assessed HBCS effects vs placebo, zoledronic acid (ZA) positive control known to inhibit osteoclasts and increase fracture callus and growth plate bone volume, and hydroxy-phenyl-ethane-hydroxy-bisphosphonate (HPHBP), the bisphosphonate component of HBCS, using a murine closed femur fracture model, and on intramembranous and endochondral ossification in the proximal tibia of 12-wk-old mice. Longitudinal X-rays and micro-CT confirmed that no treatments inhibited fracture healing, although ZA and HBCS increased callus bone volume fraction at 3 wk. Histology results suggested that this was likely due to effects on osteoclasts at 2 and 3 wk but confirmed that all soft callus was remodeled by 3 wk. HBCS did not show the increases in polar moment of inertia or maximum torque observed in the ZA group at 4 wk. Studies on unfractured fluorochrome labeled tibias demonstrated that no treatments affected mineral apposition and bone formation rates. However, HPHBP and HBCS increased growth plate bone volume over total volume (BV/TV) concomitant with a decrease in osteoclasts, while ZA further increased total bone volume and BV/TV with a dramatic increase in osteoclasts. Collectively, these data demonstrate that while HBCS decreases osteoclast numbers in vivo, it does not inhibit fracture healing or normal bone growth in mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.